The primary objective of the Monoclonal Antibody CMV Retinitis Trial is to compare the safety and efficacy of Human Anti-CMV Monoclonal Antibody versus matched placebo plus active primary treatment, for both newly diagnosed and relapsed CMV retinitis in patients with AIDS.
Showing the most recent 10 out of 370 publications